References

1. Luqmani, Y.A.; Mechanisms of drug resistance in cancer chemotherapy. Medical Principles and Practice 2005, 14, 35–48, 10.1159/000086183.
2. Qiong Wu; Zhiping Yang; Yongzhan Nie; Yongquan Shi; Daiming Fan; Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches. Cancer Letters 2014, 347, 159-166, 10.1016/j.canlet.2014.03.013.
3. Jinglu Wang; Nicole Seebacher; Huirong Shi; QuanCheng Kan; Zhenfeng Duan; Novel strategies to prevent the development of multidrug resistance (MDR) in cancer. Oncotarget 2017, 8, 84559-84571, 10.18632/oncotarget.19187.
4. Xuan Wang; Haiyun Zhang; Xiaozhuo Chen; Drug resistance and combating drug resistance in cancer. Cancer Drug Resistance 2019, 2, 141–160, 10.20517/cdr.2019.10.
5. Sabrina Dallavalle; Vladimir Dobričić; Loretta Lazzarato; Elena Gazzano; Miguel Machuqueiro; Ilza Pajeva; Ivanka Tsakovska; Nace Zidar; Roberta Fruttero; Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors. Drug Resistance Updates 2020, 50, 100682, 10.1016/j.drup.2020.100682.
6. Mesci, S.; Marakli, S.; Yazgan, B.; Yıldırım, T.; The effect of ATP-binding cassette (ABC) transporters in human cancers. International Journal of Science Letters 2019, 1, 1–14.
7. Chung-Pu Wu; Sung-Han Hsiao; Yang-Hui Huang; Lang-Cheng Hung; Yi-Jou Yu; Yu-Tzu Chang; Tai-Ho Hung; Yu-Shan Wu; Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs. Cancers 2020, 12, 195, 10.3390/cancers12010195.
8. YaQiong Zu; Zhiyong Yang; Songshan Tang; Ying Han; Jun Ma; Effects of P-Glycoprotein and Its Inhibitors on Apoptosis in K562 Cells. Molecules 2014, 19, 13061-13075, 10.3390/molecules190913061.
9. Serhan Karvar; The role of ABC transporters in anticancer drug transport. TURKISH JOURNAL OF BIOLOGY 2014, 38, 800-805, 10.3906/biy-1407-3.
10. Jurjen S. Lagas; Lin Fan; Els Wagenaar; Maria L.H. Vlaming; Olaf Van Tellingen; Jos H. Beijnen; Alfred H. Schinkel; P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 Determine the Pharmacokinetics of Etoposide. Clinical Cancer Research 2009, 16, 130-140, 10.1158/1078-0432.ccr-09-1321.
11. Suman Lal; Zee Wan Wong; Edwin Sandanaraj; Xiaoqiang Xiang; Peter Cher Siang Ang; Edmund J. D. Lee; Balram Chowbay; Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Science 2008, 99, 816-823, 10.1111/j.1349-7006.2008.00744.x.
12. Kazuhiro Satake; Megumi Tsukamoto; Yuji Mitani; Luis Octávio Regasini; Vanderlan S. Bolzani; Thomas Efferth; Hiroshi Nakagawa; Human ABCB1 confers cells resistance to cytotoxic guanidine alkaloids from Pterogyne nitens. Bio-Medical Materials and Engineering 2015, 25, 249-256, 10.3233/bme-151282.
13. Aparajitha Vaidyanathan; Lynne Sawers; Anne-Louise Gannon; Probir Chakravarty; Alison L Scott; Susan E Bray; Michelle J Ferguson; Gillian Smith; ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. British Journal of Cancer 2016, 115, 431-441, 10.1038/bjc.2016.203.
14. Paloma S. Souza; James P. Madigan; Jean-Pierre Gillet; Khyati Kapoor; Suresh V. Ambudkar; Raquel Ciuvalschi Maia; Michael M. Gottesman; King Leung Fung; Expression of the multidrug transporter P-glycoprotein is inversely related to that of apoptosis-associated endogenous TRAIL. Experimental Cell Research 2015, 336, 318-328, 10.1016/j.yexcr.2015.06.005.
15. Hanan Galski; Tamar Oved-Gelber; Masha Simanovsky; Philip Lazarovici; Michael M. Gottesman; Arnon Nagler; P-glycoprotein-dependent resistance of cancer cells toward the extrinsic TRAIL apoptosis signaling pathway.. Biochemical Pharmacology 2013, 86, 584-96, 10.1016/j.bcp.2013.06.004.
16. Amila K. Nanayakkara; Courtney A. Follit; Gang Chen; Noelle S. Williams; Pia D. Vogel; John G. Wise; Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells. Scientific Reports 2018, 8, 967, 10.1038/s41598-018-19325-x.
17. Iva Guberović; Marko Marjanović; Marija Mioč; Katja Ester; Irena Martin-Kleiner; Tatjana Šumanovac Ramljak; Kata Mlinarić-Majerski; Marijeta Kralj; Crown ethers reverse P-glycoprotein-mediated multidrug resistance in cancer cells. Scientific Reports 2018, 8, 14467, 10.1038/s41598-018-32770-y.
18. Yutong Liu; Ling Zhang; Zitai Ma; Li Tian; Yingchi Liu; Yuqing Liu; Qi Chen; Yanchun Li; Enlong Ma; Ascorbate promotes the cellular accumulation of doxorubicin and reverses the multidrug resistance in breast cancer cells by inducing ROS-dependent ATP depletion.. Free Radical Research 2019, 53, 758-767, 10.1080/10715762.2019.1628957.
19. Xu-Wei Zhou; Yuan-Zheng Xia; Ya-Long Zhang; Jian-Guang Luo; Chao Han; Hao Zhang; Chao Zhang; Lei Yang; Ling-Yi Kong; Tomentodione M sensitizes multidrug resistant cancer cells by decreasing P-glycoprotein via inhibition of p38 MAPK signaling. Oncotarget 2017, 8, 101965-101983, 10.18632/oncotarget.21949.
20. Zeting Yuan; Xiaojing Shi; Yanyan Qiu; Hui Yu; Xue He; Tingting Jia; Yu Zou; Cheng Liu; Ke Xu; Yanyan Qiu; et al. Reversal of P-gp-mediated multidrug resistance in colon cancer by cinobufagin. Oncology Reports 2017, 37, 1815-1825, 10.3892/or.2017.5410.
21. Li Chen; Xinxin Li; Miaomiao Cheng; Siyuan Wang; Qiuhong Zheng; Qinying Liu; Iso-pencillixanthone A from a marine-derived fungus reverses multidrug resistance in cervical cancer cells through down-regulating P-gp and re-activating apoptosis. RSC Advances 2018, 8, 41192-41206, 10.1039/c8ra09506j.
22. Hsiu-Ju Chen; Chia-Ying Li; Ying-Tzu Chang; Charles C.N. Wang; Hsiang-Yen Lee; Hui-Yi Lin; Chin-Chuan Hung; Taxifolin Resensitizes Multidrug Resistance Cancer Cells via Uncompetitive Inhibition of P-Glycoprotein Function.. Molecules 2018, 23, 3055, 10.3390/molecules23123055.
23. Sarah Snyder; Shamanth Murundi; Lindsey Crawford; David Putnam; Enabling P-glycoprotein inhibition in multidrug resistant cancer through the reverse targeting of a quinidine-PEG conjugate.. Journal of Controlled Release 2019, 317, 291-299, 10.1016/j.jconrel.2019.11.027.
24. Basma Salama; El-Said El-Sherbini; Gehad R. El-Sayed; Mohamed El-Adl; Koki Kanehira; Akiyoshi Taniguchi; The Effects of TiO2 Nanoparticles on Cisplatin Cytotoxicity in Cancer Cell Lines. International Journal of Molecular Sciences 2020, 21, 605, 10.3390/ijms21020605.
25. Peter H. Duesberg; Reinhard Stindl; Rüediger Hehlmann; Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalyzed by aneuploidy. Proceedings of the National Academy of Sciences 2000, 97, 14295-14300, 10.1073/pnas.97.26.14295.
26. Peter Duesberg; Reinhard Stindl; Ruediger Hehlmann; Origin of multidrug resistance in cells with and without multidrug resistance genes: Chromosome reassortments catalyzed by aneuploidy. Proceedings of the National Academy of Sciences 2001, 98, 11283-11288, 10.1073/pnas.201398998.
27. Fiamma Mantovani; Licio Collavin; Giannino Del Sal; Mutant p53 as a guardian of the cancer cell. Cell Death & Differentiation 2018, 26, 199-212, 10.1038/s41418-018-0246-9.
28. Chodimella Chandrasekhar; Pasupuleti Santhosh Kumar; Potukuchi Venkata Gurunadha Krishna Sarma; Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients. Scientific Reports 2019, 9, 2412, 10.1038/s41598-019-38672-x.
29. Graeme Greenfield; Ross McMullan; Nuala Robson; Julie McGimpsey; Mark A Catherwood; Mary Frances McMullin; Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia. BMC Hematology 2019, 19, 7, 10.1186/s12878-019-0139-2.
30. Ya-Chen Tina Shih; Jorge E Cortes; Hagop M. Kantarjian; Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study. The Lancet Haematology 2019, 6, e398-e408, 10.1016/s2352-3026(19)30087-0.
31. Lorena Infante Lara; Sabine Fenner; Steven Ratcliffe; Albert Isidro-Llobet; Michael Hann; Ben Bax; Neil Osheroff; Coupling the core of the anticancer drug etoposide to an oligonucleotide induces topoisomerase II-mediated cleavage at specific DNA sequences.. Nucleic Acids Research 2018, 46, 2218-2233, 10.1093/nar/gky072.
32. Susana M. Campos; Aromatase Inhibitors for Breast Cancer in Postmenopausal Women. The Oncologist 2004, 9, 126-136, 10.1634/theoncologist.9-2-126.
33. John A. Katzenellenbogen; Christopher G. Mayne; Benita S. Katzenellenbogen; Geoffrey L Greene; Sarat Chandarlapaty; Structural Underpinnings of Estrogen Receptor Mutations in Endocrine Therapy Resistance. Nature Reviews Cancer 2018, 18, 377-388, 10.1038/s41568-018-0001-z.
34. Behzad Mansoori; Ali Mohammadi; Sadaf Davudian; Solmaz Shirjang; Behzad Baradaran; The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Advanced Pharmaceutical Bulletin 2017, 7, 339-348, 10.15171/apb.2017.041.
35. Peng Zhang; Pan Zheng; Yang Liu; Amplification of the CD24 Gene Is an Independent Predictor for Poor Prognosis of Breast Cancer.. Frontiers in Genetics 2019, 10, 560, 10.3389/fgene.2019.00560.
36. Martin F. Fromm; Hans-Martin Kauffmann; Peter Fritz; Oliver Burk; Heyo K. Kroemer; Rolf W. Warzok; Michel Eichelbaum; Werner Siegmund; Dieter Schrenk; The Effect of Rifampin Treatment on Intestinal Expression of Human MRP Transporters. The American Journal of Pathology 2000, 157, 1575-1580, 10.1016/s0002-9440(10)64794-3.
37. Bernd Greiner; Michel Eichelbaum; Péter Fritz; Hans-Peter Kreichgauer; Oliver Von Richter; Johannes Zundler; Heyo K. Kroemer; The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. Journal of Clinical Investigation 1999, 104, 147-153, 10.1172/jci6663.
38. Ilaria Genovese; Andrea Ilari; Yehuda G. Assaraf; Francesco Fazi; Gianni Colotti; Not only P-glycoprotein: Amplification of the ABCB1- containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. Drug Resistance Updates 2017, 32, 23-46, 10.1016/j.drup.2017.10.003.
39. Reema Wahdan-Alaswad; Bolin Liu; Ann D. Thor; Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem. Cancer Drug Resistance 2020, 3, 1–20, 10.20517/cdr.2019.92.
40. Zibo Zhao; Ali Shilatifard; Epigenetic modifications of histones in cancer. Genome Biology 2019, 20, 1-16, 10.1186/s13059-019-1870-5.
41. Helai P. Mohammad; Olena Barbash; Caretha L. Creasy; Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer. Nature Medicine 2019, 25, 403-418, 10.1038/s41591-019-0376-8.
42. Helai P. Mohammad; Olena Barbash; Caretha L. Creasy; Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer. Nature Medicine 2019, 25, 403-418, 10.1038/s41591-019-0376-8.
43. E. Kaminskas; Ann T Farrell; Yong-Cheng Wang; Rajeshwari Sridhara; Richard Pazdur; FDA Drug Approval Summary: Azacitidine (5‐azacytidine, Vidaza ™ ) for Injectable Suspension. The Oncologist 2005, 10, 176-182, 10.1634/theoncologist.10-3-176.
44. Pin-Fang He; Jing-Dong Zhou; Ng-Ming Yao; Ji-Chun Ma; Xiang-Mei Wen; Zhi-Hui Zhang; Xin-Yue Lian; Zi-Jun Xu; Jun Qian; Jiang Lin; et al. Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis. Oncotarget 2017, 8, 41498-41507, 10.18632/oncotarget.17241.
45. Andrew Goey; Tristan M Sissung; Cody J Peer; William D. Figg; Pharmacogenomics and histone deacetylase inhibitors. Pharmacogenomics 2016, 17, 1807-1815, 10.2217/pgs-2016-0113.
46. Srinivas Patnaik; Anupriya; Drugs Targeting Epigenetic Modifications and Plausible Therapeutic Strategies Against Colorectal Cancer.. Frontiers in Pharmacology 2019, 10, 588, 10.3389/fphar.2019.00588.
47. Toshio Shimizu; Patricia M. Lorusso; Kyri P. Papadopoulos; Amita Patnaik; Muralidhar Beeram; Lon S. Smith; Drew W. Rasco; Theresa A. Mays; Glenda Chambers; Anna Ma; et al.Jing WangRobert LaliberteMaurizio VoiA. W. Tolcher Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors. Clinical Cancer Research 2014, 20, 5032-5040, 10.1158/1078-0432.ccr-14-0570.
48. Seiichi Okabe; Yuko Tanaka; Mitsuru Moriyama; Akihiko Gotoh; Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in Philadelphia chromosome-positive leukemia cells. Cancer Chemotherapy and Pharmacology 2020, 85, 401-412, 10.1007/s00280-019-04022-x.
49. Wengong Si; Jiaying Shen; Huilin Zheng; Weimin Fan; The role and mechanisms of action of microRNAs in cancer drug resistance. Clinical Epigenetics 2019, 11, 25, 10.1186/s13148-018-0587-8.
50. Xiaobing Liu; Xing Luo; Yuqi Wu; Ding Xia; Wei Chen; Zhenqiang Fang; Jianping Deng; Yaxing Hao; Xia Yang; Teng Zhang; et al.Luqiang ZhouYingbing WuQingqing WangJie XuXiaoyan HuLongkun Li MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells via Direct Suppression of JAG1/Notch1 Axis. Cellular Physiology and Biochemistry 2018, 50, 261-276, 10.1159/000494004.
51. Hui-Ming Lin; Iva Nikolic; Jessica Yang; Lesley Castillo; Niantao Deng; Chia-Ling Chan; Nicole K. Yeung; Eoin Dodson; Benjamin Elsworth; Calan Spielman; et al.Brian Y. LeeZoë BoyerKaylene SimpsonRoger J. DalyLisa G. HorvathAlexander Swarbrick MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer.. Scientific Reports 2018, 8, 7820, 10.1038/s41598-018-26050-y.
52. Weibin Wang; Lijun Zhao; Xueju Wei; Lanlan Wang; Siqi Liu; Yu Yang; Fang Wang; Guotao Sun; Junwu Zhang; Yanni Ma; et al.Yupei ZhaoJia Yu MicroRNA-320a promotes 5-FU resistance in human pancreatic cancer cells. Scientific Reports 2016, 6, 27641, 10.1038/srep27641.
53. Saurabh Singh; Deepak Chitkara; Virender Kumar; Stephen W. Behrman; Ram I. Mahato; miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Cancer Letters 2013, 334, 211-220, 10.1016/j.canlet.2012.10.008.
54. Kenneth K.W. To; W.W. Leung; Simon Siu-Man Ng; Exploiting a novel miR-519c–HuR–ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer. Experimental Cell Research 2015, 338, 222-231, 10.1016/j.yexcr.2015.09.011.
55. Jasmine Evert; Surajit Pathak; Xiao-Feng Sun; Hong Zhang; A Study on Effect of Oxaliplatin in MicroRNA Expression in Human Colon Cancer. Journal of Cancer 2018, 9, 2046-2053, 10.7150/jca.24474.
56. Sun-Ah Kim; Injung Kim; Sungjoo Kim Yoon; Eun Kyung Lee; Hyo‐Jeong Kuh; Indirect modulation of sensitivity to 5-fluorouracil by microRNA-96 in human colorectal cancer cells. Archives of Pharmacal Research 2014, 38, 239-248, 10.1007/s12272-014-0528-9.
57. Yibing Chen; Yucen Song; Yanjun Mi; Huan Jin; Jun Cao; Haolong Li; Liping Han; Ting Huang; Xiaofei Zhang; Shumin Ren; et al.Qian MaZhengzhi Zou microRNA-499a promotes the progression and chemoresistance of cervical cancer cells by targeting SOX6. Apoptosis 2020, 25, 205-216, 10.1007/s10495-019-01588-y.
58. Z Fan; H Cui; H Yu; Q Ji; L Kang; B Han; J Wang; Q Dong; Y Li; Z Yan; et al.X YanX ZhangZ LinY HuS Jiao MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression.. Oncogenesis 2016, 5, e197-e197, 10.1038/oncsis.2016.1.
59. F Lin; P Wang; Y Shen; X Xie; Upregulation of microRNA-224 sensitizes human cervical cells SiHa to paclitaxel.. European Journal of Gynaecological Oncology 2015, 36, 432–436.
60. Jiang Zhu; Zhengzhi Zou; Peipei Nie; Xiaoni Kou; Baoyan Wu; Songmao Wang; Zhangjun Song; Jianjun He; Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression.. Cell Death & Disease 2016, 7, e2454-e2454, 10.1038/cddis.2016.361.
61. Leticia De Mattos-Arruda; Giulia Bottai; Paolo Nuciforo; Luca Di Tommaso; Elisa Giovannetti; Vicente Peg; Agnese Losurdo; José Perez-Garcia; Giovanna Masci; Fabio Corsi; et al.Javier CortesJoan SeoaneGeorge Adrian CalinLibero Santarpia MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget 2015, 6, 37269-37280, 10.18632/oncotarget.5495.
62. Lin Lu; Fang Ju; Hui Zhao; Xuezhen Ma; MicroRNA-134 modulates resistance to doxorubicin in human breast cancer cells by downregulating ABCC1. Biotechnology Letters 2015, 37, 2387-2394, 10.1007/s10529-015-1941-y.
63. Jing Yan; Jing-Yi Jiang; Xiao-Na Meng; Yin-Ling Xiu; Zhi-Hong Zong; MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression.. Journal of Experimental & Clinical Cancer Research 2016, 35, 31, 10.1186/s13046-016-0307-1.
64. Xiaoyan Ying; Kuang Wei; Zhe Lin; Yugui Cui; Jie Ding; Yun Chen; Boqun Xu; MicroRNA-125b Suppresses Ovarian Cancer Progression via Suppression of the Epithelial-Mesenchymal Transition Pathway by Targeting the SET Protein. Cellular Physiology and Biochemistry 2016, 39, 501-510, 10.1159/000445642.
65. Eduardo Tormo; Sandra Ballester; Anna Adam-Artigues; Octavio Burgués; Elisa Alonso; Begoña Bermejo; Silvia Menéndez; Sandra Zazo; Juan Madoz-Gúrpide; Ana Rovira; et al.Joan AlbanellFederico RojoAna LluchPilar Eroles The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors. Scientific Reports 2019, 9, 5316, 10.1038/s41598-019-41472-y.
66. Y Shang; Z Zhang; Z Liu; B Feng; G Ren; K Li; L Zhou; Y Sun; M Li; J Zhou; et al.Y AnK WuY NieD Fan miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene 2013, 33, 3267-3276, 10.1038/onc.2013.297.
67. Zhiyu Wang; Neng Wang; Pengxi Liu; Qianjun Chen; Honglin Situ; Ting Xie; Jianxing Zhang; Cheng Peng; Yi Lin; Jianping Chen; et al. MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells, a process modulated by the natural autophagy inducer isoliquiritigenin. Oncotarget 2014, 5, 7013-7026, 10.18632/oncotarget.2192.
68. Sheng Chen; Jian Wu; Kai Jiao; Qiong Wu; Jiaojiao Ma; Di Chen; Jianqin Kang; Guodong Zhao; Yongquan Shi; Daiming Fan; et al.Guohong Zhao MicroRNA-495-3p inhibits multidrug resistance by modulating autophagy through GRP78/mTOR axis in gastric cancer. Cell Death & Disease 2018, 9, 1070, 10.1038/s41419-018-0950-x.
69. Sarra Setrerrahmane; Hanmei Xu; Tumor-related interleukins: old validated targets for new anti-cancer drug development. Molecular Cancer 2017, 16, 153, 10.1186/s12943-017-0721-9.
70. Yue Wang; Ye Qu; Xiu Long Niu; Wei Jia Sun; Xiao Lei Zhang; Ling Zhi Li; Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cytokine 2011, 56, 365-375, 10.1016/j.cyto.2011.06.005.
71. D Conze; L Weiss; P S Regen; A Bhushan; D Weaver; P Johnson; Mercedes Rincon; Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells.. Cancer Research 2001, 61, 8851–8858.
72. In-Hye Ham; Hye Jeong Oh; Hyejin Jin; Cheong A Bae; Sang-Min Jeon; Kyeong Choi; Sang-Yong Son; Sang-Uk Han; Rolf A. Brekken; Dakeun Lee; et al.Hoon Hur Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer. Molecular Cancer 2019, 18, 68, 10.1186/s12943-019-0972-8.
73. SaeHeum Song; M. Guillaume Wientjes; Yuebo Gan; Jessie L.-S. Au; Fibroblast growth factors: An epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proceedings of the National Academy of Sciences 2000, 97, 8658-8663, 10.1073/pnas.140210697.
74. Ana Jimenez-Pascual; Florian A Siebzehnrubl; Fibroblast Growth Factor Receptor Functions in Glioblastoma.. Cells 2019, 8, 715, 10.3390/cells8070715.
75. Takahiro Suzuki; Hiroyuki Yasuda; Koji Funaishi; Daisuke Arai; Kota Ishioka; Keiko Ohgino; Tetsuo Tani; Junko Hamamoto; Ayano Ohashi; Katsuhiko Naoki; et al.Tomoko BetsuyakuKenzo Soejima Multiple roles of extracellular fibroblast growth factors in lung cancer cells. International Journal of Oncology 2014, 46, 423-429, 10.3892/ijo.2014.2718.
76. Rishi Kant Singh; Sanjay Kumar; Pramod Kumar Gautam; Munendra Singh Tomar; Praveen Kumar Verma; Surya Pratap Singh; Arbind Acharya; Protein kinase C-α and the regulation of diverse cell responses. Biomolecular Concepts 2017, 8, 143-153, 10.1515/bmc-2017-0005.
77. Manoj K. Jena; Jagadeesh Janjanam; Role of extracellular matrix in breast cancer development: a brief update. F1000Research 2018, 7, 274, 10.12688/f1000research.14133.2.
78. Francesco Gentile; Ahmed H. Elmenoufy; Gloria Ciniero; David Jay; Feridoun Karimi‐Busheri; Khaled H. Barakat; Michael Weinfeld; Frederick G. West; Jack A. Tuszyński; Computer‐aided drug design of small molecule inhibitors of the ERCC1‐XPF protein–protein interaction. Chemical Biology & Drug Design 2020, 95, 460-471, 10.1111/cbdd.13660.
79. Rafael Rosell; Miquel Tarón; Aurelio Ariza; Agustí Barnadas; Jose Luis Mate; Noemı́ Reguart; Mireia Margelı́; Enriqueta Felip; Pedro Mendez; Rosario Garcı́a-Campelo; et al. Molecular predictors of response to chemotherapy in lung cancer. Seminars in Oncology 2004, 31, 20-27, 10.1053/j.seminoncol.2003.12.011.
80. Clarissa Ribeiro Reily Rocha; Matheus Molina Silva; Annabel Quinet; Januario Bispo Cabral-Neto; Carlos Fm Menck; DNA repair pathways and cisplatin resistance: an intimate relationship. Clinics 2018, 73, e478s, 10.6061/clinics/2018/e478s.
81. Ewan M. McNeil; Katy R. Astell; Ann-Marie Ritchie; Steven Shave; Douglas R. Houston; Preeti Bakrania; Hayley M. Jones; Puneet Khurana; Claire Wallace; Tim Chapman; et al.Martin A. WearMalcolm D. WalkinshawBarbara SaxtyDavid W. Melton Inhibition of the ERCC1–XPF structure-specific endonuclease to overcome cancer chemoresistance. DNA Repair 2015, 31, 19-28, 10.1016/j.dnarep.2015.04.002.
82. Timothy M. Chapman; Kevin J. Gillen; Claire Wallace; Maximillian Lee; Preeti Bakrania; Puneet Khurana; Peter J. Coombs; Laura Stennett; Simon Fox; Emilie A. Bureau; et al.Janet BrownleesDavid W. MeltonBarbara Saxty Catechols and 3-hydroxypyridones as inhibitors of the DNA repair complex ERCC1-XPF. Bioorganic & Medicinal Chemistry Letters 2015, 25, 4097-4103, 10.1016/j.bmcl.2015.08.031.
83. Akaash K. Mishra; Silvana S. Dormi; Alaina M. Turchi; Derek S. Woods; John J. Turchi; Chemical inhibitor targeting the replication protein A-DNA interaction increases the efficacy of Pt-based chemotherapy in lung and ovarian cancer.. Biochemical Pharmacology 2014, 93, 25-33, 10.1016/j.bcp.2014.10.013.
84. Tracy M. Neher; Diane Bodenmiller; Richard W. Fitch; Shadia I. Jalal; John J. Turchi; Novel irreversible small molecule inhibitors of replication protein A display single-agent activity and synergize with cisplatin.. Molecular Cancer Therapeutics 2011, 10, 1796-806, 10.1158/1535-7163.MCT-11-0303.
85. Navnath, S.; Gavande, N.S.; VanderVere-Carozza, P.S.; Pawelczak, K.S.; Vernon, T.L.; Jordan, M.R.; Turchi, J.J. Structure-Guided Optimization of Replication Protein A (RPA)–DNA Interaction Inhibitors. ACS Med. Chem.Lett. 2020.
86. Mark R. Kelley; Derek Logsdon; Melissa Fishel; Targeting DNA repair pathways for cancer treatment: what’s new?. Future Oncology 2014, 10, 1215-1237, 10.2217/fon.14.60.
87. Thomas Helleday; Eva Petermann; Cecilia Lundin; Ben Hodgson; Ricky A. Sharma; DNA repair pathways as targets for cancer therapy. Nature Reviews Cancer 2008, 8, 193-204, 10.1038/nrc2342.
88. Amy B. Hall; Dave Newsome; Yuxin Wang; Diane M. Boucher; Brenda Eustace; Yong Gu; Brian Hare; Mac A. Johnson; Sean Milton; Cheryl E. Murphy; et al.Darin TakemotoCrystal TolmanMark WoodPeter CharltonJean-Damien CharrierBrinley FureyJulian GolecPhilip M. ReaperJohn R. Pollard Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970. Oncotarget 2014, 5, 5674-5685, 10.18632/oncotarget.2158.
89. Frank P. Vendetti; Alan Lau; Sandra Schamus; Thomas P. Conrads; Mark J. O’Connor; Christopher J. Bakkenist; The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo. Oncotarget 2015, 6, 44289-44305, 10.18632/oncotarget.6247.
90. Nada AlBarakati; Tarek M.A. Abdel-Fatah; Rachel Doherty; Roslin Russell; Devika Agarwal; Paul Moseley; Christina Perry; Arvind Arora; Nouf AlSubhi; Claire Seedhouse; et al.Emad A. RakhaAndrew R. GreenGraham BallStephen ChanCarlos CaldasIan EllisSrinivasan Madhusudan Targeting BRCA1‐BER deficient breast cancer by ATM or DNA‐PKcs blockade either alone or in combination with cisplatin for personalized therapy. Molecular Oncology 2014, 9, 204-217, 10.1016/j.molonc.2014.08.001.
91. Jacqueline H. L. Fok; Antonio Ramos-Montoya; Mercedes Vazquez-Chantada; Paul W. G. Wijnhoven; Valeria Follia; Neil James; Paul M. Farrington; Ankur Karmokar; Sophie E. Willis; Jonathan Cairns; et al.Jenni NikkiläDavid BeattieGillian M. LamontM. Raymond V. FinlayJoanne WilsonAaron SmithLenka Oplustil O’ConnorStephanie LingStephen E. FawellMark J. O’ConnorSimon J. HollingsworthEmma DeanFrederick W. GoldbergBarry R. DaviesElaine B. Cadogan AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.. Nature Communications 2019, 10, 5065-15, 10.1038/s41467-019-12836-9.
92. David A. Alagpulinsa; Srinivas Ayyadevara; Robert Joseph Shmookler Reis; A Small-Molecule Inhibitor of RAD51 Reduces Homologous Recombination and Sensitizes Multiple Myeloma Cells to Doxorubicin. Frontiers in Oncology 2014, 4, 289, 10.3389/fonc.2014.00289.
93. Jessica L. Wojtaszek; Nimrat Chatterjee; Javaria Najeeb; Azucena Ramos; Minhee Lee; Ke Bian; Jenny Xue; Benjamin A. Fenton; Hyeri Park; Deyu Li; et al.Michael T. HemannJiyong HongGraham C. WalkerPei Zhou A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy. Cell 2019, 178, 152-159.e11, 10.1016/j.cell.2019.05.028.
94. Kinrin Yamanaka; Nimrat Chatterjee; Michael T. Hemann; Graham C. Walker; Inhibition of mutagenic translesion synthesis: A possible strategy for improving chemotherapy?. PLOS Genetics 2017, 13, e1006842, 10.1371/journal.pgen.1006842.
95. Akira Inoue; Sotaro Kikuchi; Asami Hishiki; Youming Shao; Richard Heath; Benjamin J. Evison; Marcelo Actis; Christine E. Canman; Hiroshi Hashimoto; Naoaki Fujii; et al. A Small Molecule Inhibitor of Monoubiquitinated Proliferating Cell Nuclear Antigen (PCNA) Inhibits Repair of Interstrand DNA Cross-link, Enhances DNA Double Strand Break, and Sensitizes Cancer Cells to Cisplatin. Journal of Biological Chemistry 2014, 289, 7109-7120, 10.1074/jbc.m113.520429.
96. Vibhavari Sail; Alessandro A. Rizzo; Nimrat Chatterjee; Radha Charan Dash; Zuleyha Ozen; Graham C. Walker; Dmitry M. Korzhnev; M. Kyle Hadden; Identification of Small Molecule Translesion Synthesis Inhibitors That Target the Rev1-CT/RIR Protein−Protein Interaction. ACS Chemical Biology 2017, 12, 1903-1912, 10.1021/acschembio.6b01144.
97. Ubaldo Gioia; Sofia Francia; Matteo Cabrini; Silvia Brambillasca; Flavia Michelini; Corey W. Jones-Weinert; Fabrizio Daddadifagagna; Pharmacological boost of DNA damage response and repair by enhanced biogenesis of DNA damage response RNAs.. Scientific Reports 2019, 9, 6460, 10.1038/s41598-019-42892-6.
98. Shelly Pathania; Rohit Bhatia; Ashish Baldi; Randhir Singh; Ravindra K. Rawal; Drug metabolizing enzymes and their inhibitors' role in cancer resistance. Biomedicine & Pharmacotherapy 2018, 105, 53-65, 10.1016/j.biopha.2018.05.117.
99. Yan Li; Albert Steppi; Yidong Zhou; Feng Mao; Philip Craig Miller; Max M. He; Tingting Zhao; Qiang Sun; Jinfeng Zhang; Tumoral expression of drug and xenobiotic metabolizing enzymes in breast cancer patients of different ethnicities with implications to personalized medicine.. Scientific Reports 2017, 7, 4747, 10.1038/s41598-017-04250-2.
100. Emma Ramsay; Pierre J Dilda; Glutathione S-conjugates as prodrugs to target drug-resistant tumors. Frontiers in Pharmacology 2014, 5, 181, 10.3389/fphar.2014.00181.
101. John O. Miners; Nuy Chau; Andrew Rowland; Kushari Burns; Ross McKinnon; Peter I. MacKenzie; Geoffrey T Tucker; Kathleen M Knights; Ganessan Kichenadasse; Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia. Biochemical Pharmacology 2017, 129, 85-95, 10.1016/j.bcp.2017.01.002.
102. Michael J. Osborne; Luciana Coutinho De Oliveira; Laurent Volpon; Hiba Ahmad Zahreddine; Katherine L. B. Borden; Overcoming Drug Resistance through the Development of Selective Inhibitors of UDP-Glucuronosyltransferase Enzymes. Journal of Molecular Biology 2019, 431, 258-272, 10.1016/j.jmb.2018.11.007.
103. Jennifer Wu; Charles Henderson; Lynn Feun; Peter Van Veldhuizen; Philip Gold; Hui Zheng; Theresa Ryan; Lawrence S. Blaszkowsky; Haobin Chen; Max Costa; et al.Barry RosenzweigMarylynn NierodzikHoward HochsterFranco MuggiaGiovanni AbbadessaJonathan LewisAndrew X. Zhu Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma. Investigational New Drugs 2009, 28, 670-676, 10.1007/s10637-009-9286-9.
104. Mine Aksoy; Irfan Küfrevioglu; Inhibition of human erythrocyte glutathione S-transferase by some flavonoid derivatives. Toxin Reviews 2017, 37, 251-257, 10.1080/15569543.2017.1345945.
105. Muhammet Serhat Özaslan; Yeliz Demir; Hatice Esra Aslan; Şükrü Beydemir; Ömer Irfan Küfrevioğlu; Evaluation of chalcones as inhibitors of glutathione S-transferase. Journal of Biochemical and Molecular Toxicology 2018, 32, e22047, 10.1002/jbt.22047.
106. Wang Feifei; Xu Honghai; Yan Yongrong; Wu Pingxiang; Wu Jianhua; Zhu Xiaohui; Li Jiaoying; Sun Jingbo; Zhou Kun; Ren Xiaoli; et al.Qi LuLan XiaoliangCheng ZhiqiangTang NaLiao WentingYanqing DingLiang Li FBX8 degrades GSTP1 through ubiquitination to suppress colorectal cancer progression. Cell Death & Disease 2019, 10, 351, 10.1038/s41419-019-1588-z.
107. Huanhuan Lv; Chenxiao Zhen; Junyu Liu; Pengfei Yang; Lijiang Hu; Peng Shang; Unraveling the Potential Role of Glutathione in Multiple Forms of Cell Death in Cancer Therapy.. Oxidative Medicine and Cellular Longevity 2019, 2019, 3150145-16, 10.1155/2019/3150145.
108. Sofia C. Nunes; Jacinta Serpa; Glutathione in Ovarian Cancer: A Double-Edged Sword. International Journal of Molecular Sciences 2018, 19, 1882, 10.3390/ijms19071882.
109. Ankita Bansal; M. Celeste Simon; Glutathione metabolism in cancer progression and treatment resistance. Journal of Cell Biology 2018, 217, 2291-2298, 10.1083/jcb.201804161.
110. Enrico Desideri; Fabio Ciccarone; Maria Rosa Ciriolo; Targeting Glutathione Metabolism: Partner in Crime in Anticancer Therapy.. Nutrients 2019, 11, 1926, 10.3390/nu11081926.
111. Hideaki Ogiwara; Kazuaki Takahashi; Mariko Sasaki; Takafumi Kuroda; Hiroshi Yoshida; Reiko Watanabe; Ami Maruyama; Hideki Makinoshima; Fumiko Chiwaki; Hiroki Sasaki; et al.Tomoyasu KatoAikou OkamotoTakashi Kohno Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers. Cancer Cell 2019, 35, 177-190.e8, 10.1016/j.ccell.2018.12.009.
112. Young-Sun Lee; Dae-Hee Lee; So Yeon Jeong; Seong Hye Park; Sang Cheul Oh; Yong Seok Park; Jian Yu; Haroon A Choudry; David L Bartlett; Yong J. Lee; et al. Ferroptosis‐inducing agents enhance TRAIL‐induced apoptosis through upregulation of death receptor 5. Journal of Cellular Biochemistry 2018, 120, 928-939, 10.1002/jcb.27456.
113. Xiaofen Pan; Zhixiu Lin; Danxian Jiang; Ying Yu; Donghong Yang; Hechao Zhou; Dechao Zhan; Sha Liu; Gang Peng; Zihong Chen; et al.Zhong-Hua Yu Erastin decreases radioresistance of NSCLC cells partially by inducing GPX4-mediated ferroptosis. Oncology Letters 2019, 17, 3001-3008, 10.3892/ol.2019.9888.
114. Judith Villablanca; Samuel L. Volchenboum; Hwangeui Cho; Min H. Kang; Susan L. Cohn; Clarke P. Anderson; Araz Marachelian; Susan Groshen; Denice Tsao-Wei; Katherine Matthay; et al.John M. MarisCharlotte E. HasenauerScarlett CzarneckiHollie LaiFariba GoodarzianHiro ShimadaC. Patrick Reynolds A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatric Blood & Cancer 2016, 63, 1349-1356, 10.1002/pbc.25994.
115. Daniela Catanzaro; Edoardo Gaude; Genny Orso; Carla Giordano; Giulia Guzzo; Andrea Rasola; Eugenio Ragazzi; Laura Caparrotta; Christian Frezza; Monica Montopoli; et al. Inhibition of glucose-6-phosphate dehydrogenase sensitizes cisplatin-resistant cells to death. Oncotarget 2015, 6, 30102-30114, 10.18632/oncotarget.4945.
116. Mohamed Elgendy; Marco Cirò; Amir Hosseini; Jakob Weiszmann; Luca Mazzarella; Elisa Ferrari; Riccardo Cazzoli; G. Curigliano; Andrea DeCensi; Bernardo Bonanni; et al.Alfredo BudillonPier Giuseppe PelicciVeerle JanssensManfred OgrisManuela BaccariniLuisa LanfranconeWolfram WeckwerthMarco FoianiSaverio Minucci Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3β-MCL-1 Axis.. Mohamed Elgendy; Marco Cirò; Amir Hosseini; Jakob Weiszmann; Luca Mazzarella; Elisa Ferrari; Riccardo Cazzoli; G. Curigliano; Andrea DeCensi; Bernardo Bonanni; et al.Alfredo BudillonPier Giuseppe PelicciVeerle JanssensManfred OgrisManuela BaccariniLuisa LanfranconeWolfram WeckwerthMarco FoianiSaverio Minucci Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3β-MCL-1 Axis. Cancer Cell 2019, 35, 798-815.e5, 10.1016/j.ccell.2019.03.007.